Canada [français] | Apotex Worldwide

About us

For media inquiries, please contact us here

Apotex Inc.
150 Signet Drive,
North York,
ON, M9L 1T9
Canada
Email

News

September 30, 2021

VOLUNTARY NATIONWIDE RECALL: ONE LOT OF Mirvala™ 28 (Desogestrel and Ethinyl Estradiol Tablets, USP) 0.150 mg / 0.030 mg DUE TO POSSIBILITY OF ONE PLACEBO PILL IN PLACE OF AN ACTIVE PILL
September 27, 2021

Canadian Cancer Patients Have New Affordable Treatment Option
September 1, 2021

CANADIAN-MADE GENERIC OPTION TO TREAT MULTIPLE MYELOMA NOW AVAILABLE
April 29, 2021

Voluntary Recall of one (1) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot PY1831.
April 15, 2021

GOVERNMENT OF CANADA AWARDS APOTEX INC. A SIGNIFICANT CONTRACT TO SUPPLY A SAFETY NET OF ADDITIONAL DEXAMETHASONE IN CANADA
April 13, 2021

Voluntary Recall of one (1) lot of APO- AMITRIPTYLINE (Amitriptyline Hydrochloride Tablets USP) 10 mg – Lot RF0410.
June 12, 2020

Voluntary Recall of APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) 500mg Tablets.
May 26, 2020

Canada’s largest pharmaceutical manufacturer donates thousands of bottles of hand sanitizer to hospitals across Quebec
May 25, 2020

Toronto Company Launches Hiring Blitz During COVID-19
April 21, 2020

Canada’s Apotex Donates Two Million Dosages of Hydroxychloroquine to the Public Health Agency of Canada
April 17, 2020

Canada's Apotex Donates Critical N95 Masks to Support Frontline Healthcare Workers
April 13, 2020

Canada's Largest Pharmaceutical Company Produces Hand Sanitizer to Support the Fight Against COVID-19
March 20, 2020

Apotex Donates Hydroxychloroquine for a Clinical Study to Prevent Infection From Covid-19 With Front Line Health Care Workers
February 4, 2020

Voluntary Recall of APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) 500mg Tablets.
December 5, 2019

Apotex Releases New Supply of Tamoxifen into Canadian Market

Canada’s leading generic drug manufacturer, Apotex, announced today that its first shipment of the drug tamoxifen has been released to the Canadian market. Additional releases are scheduled for December 2019 and January 2020.
June 1, 2018

Apotex Builds Momentum in Canada's Biosimilar Market After World's First Approval

Health Canada Leads the Way by Approving the First-Ever Pegfilgrastim Biosimilar in any Highly Regulated World Market
September 1, 2017

VOLUNTARY NATIONWIDE RECALL: One lot of APO-NITROGLYCERIN (Nitroglycerin Sublingual Spray) Apotex standard, 0.4MG/Metered dose due to possibility of non-spraying pump
February 9, 2017

VOLUNTARY NATIONWIDE RECALL: One lot of ALYSENA™ 28 (Levonorgestrel and Ethinyl Estradiol tablets, USP 100 mcg/20 mcg) Due to Possibility of Broken/Chipped Tablets
March 31, 2016

Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets

Apobiologix^®, a Division of Apotex Inc., today launched Grastofil^®, its first subsequent entry biologic (SEB) approved in Canada.
March 24, 2016

Apotex Launches First Generic Version of Merck's Nasonex®

Apotex Inc. announced today that it has launched the first generic version of Merck's Nasonex^® nasal spray (mometasone furoate monohydrate) in the United States.